ARP

ARP Therapeutics is a biotechnology company focused on developing a new class of small molecule drugs that target RNA-binding proteins (RBPs). By leveraging its proprietary platform, the company aims to modulate the post-transcriptional regulation of gene expression to treat complex diseases such as cancer and inflammatory disorders. ARP's approach addresses targets previously considered undruggable, potentially offering novel therapeutic options for patients with high unmet medical needs. The company is currently in the pre-clinical stage, advancing a pipeline of candidates designed to disrupt disease-driving protein-RNA interactions.